Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
There are some notable program updates in the latest device user fee agreement regarding Pre-Submissions and “America First” fees, but the draft MDUFA VI framework presented at FDA headquarters this week is much more about stability than disruption.
The precision oncology market is estimated to be $80-100 billion, with less than 20% penetration. In a video interview, Kyle Mikson of Canaccord Genuity explains how top competitors like Guardant Health, Natera, Grail, Tempus, GeneDx, and others are set to benefit and the catalysts driving adoption.
Industry and hospital groups call out CMS for tightening its proposed coverage policy language for transcatheter aortic valve replacements. Excerpted from Pathways Picks July 23: TEMPO Selection, TAVR Coverage, AI Picks, and India’s Software Guidance.